Armata Pharmaceuticals Inc

ASE:ARMP   3:59:56 PM EDT
-0.40 (-8.15%)

Armata Pharma Gets FDA IND Clearance For Phase 1B/2A Study Of Staphylococcus Aureus Bacteremia Treatment

Published: 11/18/2021 13:27 GMT
Armata Pharmaceuticals Inc (ARMP) - Armata Pharmaceuticals Provides Regulatory and Clinical Update Reflecting Sustained Progress Across Key Phage Therapeutic Development Programs.
Armata Pharmaceuticals Inc - Announces FDA Clearance of Ind to Initiate Phase 1b/2a Clinical Trial of Ap-sa02 in Staphylococcus Aureus Bacteremia.
Armata Pharmaceuticals Inc - Expects to Initiate a Phase 1b/2a Clinical Study of Ap-sa02 by End of This Year.